SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance.

Front Oncol · 2025 · PMC12324164 · PMID 40766331

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp = 0.053so close (0.05 < p ≤ 0.1)

Similarly, in a dataset of 110 ovarian cancer patients who received cisplatin chemotherapy, high SLFN11 expression showed a trend associated with longer OS (p = 0.053).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.